Study in Patients With Moderated to Severe Rheumatoid Arthritis Who Have Failed to Combination Therapy of Conventional Disease-modifying Antirheumatic Drugs (cDMARDs) to cDMARD Plus ANti-TNF Versus cDMARDs in Real World
N/A
This study will be conducted to observe the disease activity change of Conv...
Status
Completed
Location
Eisai Trial Site # 1
Start Date
2017-09-11
Trial ID
NCT03264703
A Moderate to Severe Rheumatoid Arthritis Study
PHASE3
The purpose of this study is to determine whether baricitinib 4 milligram (...
Status
Completed
Location
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Moderate to Severe Rheumatoid Arthritis Participants
PHASE3
The purpose of this study is to determine whether baricitinib 4 milligram (...
Status
Completed
Location
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
EMBRACE-SC: Observational Study of Subcutaneous (SC) Tocilizumab Alone or in Combination With Conventional Disease-Modifying Antirheumatic Drugs (cDMARDs) in Rheumatoid Arthritis
N/A
The purpose of this study is to evaluate the percentage of participants tre...